Anti-leucosis and anti-microbial composition |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IPC classes for russian patent Anti-leucosis and anti-microbial composition (RU 2339376):
  
![Dimers of pyrrol[2,1-c][1,4]benzodiazepine as antitumoral agents and method of their obtaining](http://img.russianpatents.com/img_data/162/1628552-s.gif) Dimers of pyrrol[2,1-c][1,4]benzodiazepine as antitumoral agents and method of their obtaining / 2338747
New derivatives of pyrrol[2,1-c][1,4]benzodiazepine of the general formula
 New physiologically active substances / 2338741
Invention pertains to new compounds with general formula (I)
 Polyactive terpenoid substance abisil-2, pharmaceutical composition on its basis and ways of its application / 2338547
Agent possessing wound-healthing, antiinflammatory, antibacterial, immunomodulating, anaesthetising and antitumoral activity on a basis of terpenoids, contains a capsule extract of plants of Pinaceae bloodline exposed to short-term stressful influence, enriched with monoterpenes, obtained from a capsule extract. The pharmaceutical composition possessing wound-healthing, antiinflammatory, antibacterial, immunomodulating, anaesthetising and antitumoral activity, contains the above described agent in effective quantity and the target additive. Application of the above described agent for preparation of a medicinal preparation for treatment of pyoinflammatory diseases.
Method of neoadjuvant chemotherapy of mammary gland cancer / 2338545
From the first day of treatment centrifugate the autoblood obtained by vascular access in volume of 2400-2600 ml, 1600 ml of supernatant plasmas select in sterile vials, expose to filtrational detoxicating with use of filter F60S with rate of perfusion of 250-300 ml/minute. Then the obtained albuminous concentrate of autoplasma in volume 700-800 ml place in sterile vials in the equal portions corresponding to number of planned introductions of cytostatics under the scheme. Vials contain in a refrigeration cabinet at t-20°C. At carrying out of polychemotherapy by cytostatics under the scheme, an albuminous concentrate defreeze at t +4°C, each antitumoral preparation plant in 10 ml of a normal saline solution, enter into a vial with an albuminous concentrate, incubate at t +37.0°C within not less than 30 minutes and reinfuse them intravenously driply, spend 1-2 courses of neoadjunt treatment.
Combined therapy for treatment of acute leukemia and myelodisplastic syndrome / 2338535
Invention can be used for treatment of an acute myelogenetic leukemia or myelodysplastic syndrome. For this purpose use a combination of preparations hemetuzumab ozohamicin, daunorubicin and cytarabinum in certain doses and regimens.
 Staufosporine derivatives as inhibitors of receptor tyrosine kinase flt3 activity / 2337692
Invention concerns application of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9N-diindolo [1,2,3-gh:3', 2', 1'-lm] pyrrolo[3,4-j][1,7]benzodiasonine-11-yl]-N-methylbenzamide of formula
 Antitumoral agent on basis of immunopolisome biological structure, way of its obtaining and vectorial delivery in central nervous system at tumoral process / 2336901
Invention concerns biopharmacology and medicine area. The antitumor agent representing a immunoliposome biological structure, including a liposome containing the therapeutic agent, sewed with a vector of peptide nature, thus for treatment of CNS tumors is declared, the liposome contains the therapeutic agent in a water phase, as a vector contains monoclonal antibodies to CD34+, and a linking represents 2-iminotiolan (IT) in 0.1% concentration. As a therapeutic agent, immunoliposome contains the substance chosen from the group: Daunomycin, Carminomycinum, Melphtalan, Methotrexatum, Cytarabinum, Doxorubicinum, Ricine. The method of obtaining of an antitumoral agent and way of inhibition of a tumor of the brain, consisting in agent administering due to item 1 in a pharmaceutically suitable carrier in effective quantity is declared also. Thus preliminary administer parenterally a preparation of hematological stem cells CD34+.
Method of obtaining shelf fungus ethanolic extract / 2336888
Invention concerns the pharmaceutical, food and cosmetic industry. Perform extraction of the raw material crushed with water with obtaining of a water extract and pulp. The pulp, obtained after extraction of raw materials by the water, is extracted in two steps with ethyl alcohol. At the first step of extraction the constrictor is extracted within 4-6 hours using the following proportion: ethyl alcohol 1:(5-7) with concentration of alcohol of 30% either 50%, or 70%, at temperature of 60-75°C, obtaining an ethanolic extract of the first step of extraction and pulp; then, this pulp is repeatedly extracted within 4-6 hours with ethyl alcohol using the following proportion: ethyl alcohol 1:(3-5) with concentration of alcohol of 30% either 50%, or 70%, at temperature of 60-75°C, obtaining an ethanolic extract of the second step of extraction and pulp. After that the ethanolic extract of the first step of extraction is aggregated with the ethanolic extract of the second step of extraction.
 Pyrimidine derivatives, characterised by antiproliferative activity, and pharmaceutical composition / 2336275
Invention relates to new pyrimidine derivatives of formula I and their pharmaceutically acceptable salts, which are selective inhibitors of kinases KDR, FGFR and PDGFR and can be used for treatment of oncological diseases. Compound of formula I corresponds to structural formula
Method of rectal cancer treatment / 2336038
Within preoperative period patients are drew with blood sample in amount 200 ml. Using centrifugation process plasma is separated from blood. Autoplasma in amount 40 ml is placed to the first bottle added with 5-fluorouracil 500 mg. The second bottle contains remained blood corpuscles, plasma and 5-fluorouracil 1000 mg. Bottles are incubated separately within 40 minutes at 37°C. Then rectum is excised. During operation incubated blood of the second bottle with chemical added is introduced intravenously drop-by-drop. After tumour rectum is extracted, haemostatic sponge impregnated with incubated autoplasma of the first bottle with chemical added is placed in tumour box (on sacral bone). Then perineal wound is tampon or cut down.
 Agent for external application, possessing antiviral activity / 2338553
Essence of the invention includes an agent for external application which structure includes a peptide from the allopherones group, allostatin-1 and auxiliary substances. The offered agent is applied to treatment of diseases of a skin and mucosa caused by a virus of herpes, a virus of papilloma, and also cosmetic defects of a skin.
 Agent for virus diseases prevention and treatment and method of virus diseases prevention and treatment / 2337703
Invention concerns prevention and treatment of virus diseases. For this purpose heptapeptide Selank of formula Thr-Lys-Pro-Arg-Pro-Gly-Pro is applied.
Prevention method of acute respiratory infections for frequently and recurrently sick children / 2336874
Prevention method of acute respiratory infections is developed for children with frequent recurrent diseases of respiratory tract. It consists in simalteneous administration of arbidol - 1 tablet (50 mg) twice a week during 3-4 weeks combined with selenium-active - 0.5 tablet (25 mcg of selenium) once a day during 3-4 weeks. In the course of 12 months the method helps to reduce frequency and general time duration of respiratory diseases by factor of 1.9 due to simulteneous correction of immune and metabolic state disorders.
 Immunogenic vaccine / 2333770
Invention concerns medicine, particularly an immunogenic composition capable of activating immune response to poliomyelitis virus. The invention claims an immunogenic composition including deactivated poliomyelitis virus, bacterial polysaccharide or oligosaccharide and stabiliser, in the dried form. After recovery the composition can activate immune response to poliomyelitis virus. The invention also concerns a method for obtaining the claimed composition.
 Antiviral medicine / 2333753
Invention concerns chemical pharmaceutical industry, particularly a medicine for treatment of viral disease, including HIV infection (AIDS and HIV related diseases). The antiviral medicine is a solution containing fullerene-polyhydropolyaminocaproic acid and dimethyl sulfoxide in the following component content per ampoule: fullerene-polyhydropolyaminocaproic acid 50 mg, dimethyl sulfoxide up to 0.5 ml. The medicine is intended for intramuscular or intravenous (drip-feed) administration, and dissolved in 20 ml of water for intramuscular administration, while the variant for intravenous administration includes additionally 20 ml of 0.9% sodium chloride solution per 1 ampoule.
 Antiviral medicine / 2333752
Invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a 1% ointment containing fullerene-polyhydropolyaminocaproic acid as active substance and auxiliary substances of dimethylsulfoxide, water-free lanolin and Vaseline in the following amount (g): fullerene-polyhydropolyaminocaproic acid 1.0, diemthylsulfoxide 10.0, water-free lanolin 10.0, Vaseline up to 100.0.
 Antiviral medicine / 2333751
Invention concerns chemical pharmaceutical industry, particularly medicine for treatment of virus diseases, including HIV infection (AIDS and HIV-related diseases). The antiviral medicine is a suppository containing fullerene-polyhydropolyaminocaproic acid and auxiliary substances of dimethylsulfoxide, water-free lanolin or vegetable oil selected out of olive, peach, bumpkin seed oil, and base selected out of W-35 or H-15 vitepsol, cacao butter, solid fat, in the following amount per one 2 g suppository: fullerene-polyhydropolyaminocaproic acid 5-20 mg, diemthylsulfoxide 50-200 mg, water-free lanolin or vegetable oil 20-100 mg, the rest being the base.
 Isoflavon derivatives of tectorigenine, their production and virus inactivating agent containing these derivatives as an active ingredient / 2332410
Invention relates to the new isoflavon derivative of tectorigenine compound of formula (II)
Medicine for bird influenza treatment / 2332236
Medicine for bird influenza treatment includes activated-potentiated form of antibodies to bird alpha, beta and gamma interferon obtained by multiple sequential cultivation and external affection by homeopathic technology.
Method of preventive poliomyelitis vaccination in far north / 2332232
By the first vaccination of 3-18 months old children vaccination is performed at least over 60 days after their arrival to Far North regions from other climatic zones.
Method for treatment of extensive peritonitis / 2339368
Invention relates to medicine, particularly to abdominal surgery, and applied to treatment for extensive peritonitis. To do it during operative intervention the peritonitis source is eliminated, and abdominal cavity sanation is performed. Then 3% methylcellulose gel, preliminary saturated with 1200 mg/l sodium hypochlorite solution in proportion 3:1, is introduced.
|
FIELD: medicine. SUBSTANCE: invention relates to veterinary and medicine, particularly substances with cytostatic and bactericidal properties; it can be applied in pharmaceutical industry. The water-soluble composition includes, in wt %: 0.007 to 0.7 metronidazole, 0.0085 to 0.85 silver hexamethylenetetramine nitrate, 0.0284 to 2.84 sodium thiosulphate, water or physiological solution to 100. EFFECT: obtaining of composition with cytostatic and bactericidal activity, lowered toxicity, and expanded storage time; it is inexpensive, can be prepared in the field, and moreover effective in therapy for leucosis in cattle 4 tbl, 6 ex
The invention relates to the field of veterinary medicine, namely to substances with cytotoxic and bactericidal activity, and can be used for the pharmaceutical industry. Known composition for the prevention of leukemia in cattle (cattle) on the basis of derivatives of 5-intorimidazole, including as a drug metronidazole in combination with iodized salt (U.S. Pat. RU # 2212887, 2003). The daily rate of metronidazole is 1.0 g/bird., iodized salt is from 70 to 90 g/bird., while metronidazole and iodized table salt used per os (via the gastrointestinal tract) courses once a day for 30 days every 6 months. The drug provide animals with food, but it is not suitable for intravenous injection, the treatment process them very long and not very effective. Well-known drug used mainly as a means of prevention of disease of young cattle. Closest to the claimed solution on purpose, essential features and the achieved effect is cytotoxic and antiviral medication that contains (wt.%): hexamethylenetetramine, or imidazole, or an antipyrine - 0,007-0,70; silver nitrate - 0,0085-0,85; sodium thiosulfate - 0,0284-2,84; water or eziologicheskie solution to 100% (U.S. Pat. EN 2094048, 1997). Known from the patent No. 2094048 composition selected for the prototype. Famous drug is quite effective in the treatment and prevention of leukemia cattle. The disadvantage of the prototype is a small storage period: in dissolved form, it is stored not more than two months. In a mixture of powders of this composition is not stored, because the main components when mixed react and there is a qualitative change in the properties of the composition. Currently, due to the presence of more efficient means hexamethylenetetramine is not widely implemented, and phenazone is deprecated dosage form and removed from production. Part of the silver salt has a relatively high toxicity. The objective of the invention is to develop more effective compositions based on salts of silver with cytotoxic and antibacterial activity, reduced toxicity and increased shelf life. This task is solved by the fact that according to the proposed solution anti-leukemia and anti-bacterial composition comprising a salt of silver, sodium thiosulfate and water or saline solution as the basis, instead of the inefficient contains hexamethylenetetramine as the actual beginning of metronidazole (trichopol), and instead of silver nitrate contains discotex is know salt silver - nitrate hexamine silver in the following ratio, wt.%:
Our studies showed that the storage of powders in a mixture of the components proposed composition of the fully retains its properties over 12 months. Due to this, there is a possibility of its application in various pharmaceutical forms such as solutions for injection, powders, ointments. In the treatment of leukemia injection of metronidazole is more effective than the use of per os, as in counterparts. Through the blood, it is distributed in many tissues and body fluids, in particular in bone and blood. In the treatment of leukemia property is used metronidazole easy to penetrate into the cerebrospinal fluid (up to 43% of the concentration in the blood plasma). Binding to plasma proteins is less than 20%. Up to 50-60% of metronidazole is metabolized in the liver by hydroxylation and linking with glucuronic acid, the main metabolite (2-oxymoronical) also provides the anti-Christ. protozone and antimicrobial effects. It is also important that part of the proposed composition of nitrate hexamine silver is almost 4 times less toxic than silver nitrate used in the prototype. Specific examples. If you run the examples used an aqueous solution of the composition, including known drugs: metronidazole, sodium thiosulfate and nitrate hexamine silver with structural formula
when various quantitative combinations of components. Example 1. To the mixture 0,007 g of metronidazole, 0,0085 g nitrate hexamine silver, 0,0284 g sodium thiosulfate, water is added to 100, Get a clear solution, which examined the cytotoxic and antiviral activity. Example 2. 0.07 g of metronidazole mixed with 0,284 sodium thiosulfate, type of 0.085 g of nitrate hexamine silver dissolved in 99,561 g of water. Get a transparent liquid, which examined the cytotoxic and antibacterial activity. Example 3. 0,85 g nitrate hexamine silver mixed with 0.7 g of metronidazole, add 2,84 g of dissolved sodium thiosulfate. The toxicity of the composition increases the toxicity of the cytotoxic drug cisplatin. Example 4. 0.001 g of nitrate hexamine silver and 0.003 g of metronidazole mix is, add 0,0284 g of sodium thiosulfate dissolved in water. Low toxicity, with the lack of bactericidal activity. Example 5. 0.9 g of nitrate hexamine silver mixed with 0.8 g of metronidazole and added 2.9 g of sodium thiosulfate dissolved in water. In solution noticeable residue, disappearing when heated to 40°C. Example 6. 1.0 g of nitrate hexamine silver mixed with 0.07 g of metronidazole, add 1.1 g sodium thiosulfate dissolved in water. The composition is examined for cytotoxic and antibacterial activity. Experimental evidence of the materiality of the declared characteristics, are given in tables. Studies of acute toxicity of the optimal composition according to example 2 was conducted on 75 mice BALB/c mice with intraperitoneal administration of the composition in aqueous solution in the range from 20 mg/kg to 100 mg/kg (table 1). Observation of the animals was carried out within 30 days. For comparison, the selected known drugs: silver nitrate and cisplatin. The toxicity of the claimed composition is markedly lower than the toxicity of known drugs. So, at the dosage of 60 to 70 mg/kg body weight toxicity is not detected at the dose of 80 mg/kg in comparison with nitrate of silver it is below 2.5 times. Table 2 contains the data for the study of antitumor activity of this Declaration, the act of composition and related drugs without metronidazole in CBA mice with Ehrlich carcinoma (with three times intraperitoneally). From table 2 it is seen that the use of the proposed composition causes statically significant (P<0.001) increase in 2 times the lifespan of CBA mice with Ehrlich carcinoma in comparison with control (untreated). Assessed the antitumor cytotoxic activity of the claimed composition in comparison with cisplatine on culture leukemia cell line K-562, cultivated in the medium PMI-1640 with 15%fetal calf serum, after dyeing dye Trifanova blue after 48 h of incubation. The proposed structure has a pronounced inhibitory effect on the proliferation of leukemia (tumor) cells, static reliability of the results P<0,001, and cytotoxic activity of the composition is comparable with known drug cisplatin (table 3). Antibacterial activity the proposed composition was determined by the method of serial dilutions of drugs in bacterial cultures at various concentrations (table 4). The results of the experiments considered after 24 h incubation at body temperature of a sick animal. From the data of table 4, it follows that the claimed composition has a pronounced cytotoxic effect on bacterial cells, causing 100%mortality at the stated concentrations (90% on the boundary of the range). The analysis of the level of drugs, held suavitel is m, has allowed to establish that available in the patent and medical sources there are no analogues characterized by a set of characteristics is identical for all features of the claimed matter. Therefore, the claimed invention meets the condition of patentability "novelty". Search known solutions in this and related fields in order to identify characteristics that match with the distinctive features of the prototype, not identified solutions having attributes that exactly match the distinctive features of the invention. Fame and the obvious influence of the declared distinctive signs on the achievement of the technical result is not confirmed. This allows to speak about the compliance of the claimed solution to the condition of patentability "inventive step". Sources used 1. Pat. RU # 2212887, MKI AC 31/00. Method for the prevention and treatment of leukemia in cattle. Publ. 2003.09.27. 2. Pat. EN 2094048, MKI AC 33/38. Cytotoxic and antiviral composition. Publ. 27.10.97, the Prototype. 3. Belenky, M. elements of a quantitative evaluation of the pharmacological effect. Riga, 1963. - 130 C.
Anti-leukemia and anti-bacterial composition comprising a salt of silver, sodium thiosulfate and water/saline solution as a base, characterized in that it additionally contains metronidazole, as well as salts of silver nitrate hexamine silver under the following ratios, wt.%:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||